- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:46 | Sublingual semaglutide offered to UK practices despite Novo Nordisk concerns | ||
| 12:46 | J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout | ||
| 12:46 | miRecule and Rio Biofarma to develop RNA therapeutic delivery technologies | ||
| 10:46 | Resilience and Lilly to increase US medicines production with $750m investment | ||
| Do | Pfizer seeks label expansion for Litfulo after double Phase III NSV win | ||
| Do | EU regulatory roundup: AbbVie, Pfizer & BioNTech and Incyte net approvals | ||
| Do | FDA AdCom shuns Capricor's DMD cell therapy amid data dispute | ||
| Do | The $1.2tn untapped pharma opportunity in tropical conservation | ||
| Do | Amgen's Repatha receives positive CHMP opinion for broader cardiovascular use | ||
| Do | Synlogic and Caldera sign merger agreement | ||
| Mi | AdCom expected for uniQure's Huntington's gene therapy, chief medical officer says | ||
| Mi | GSK eyes future growth with cost-cutting plan amid promising Q2 | ||
| Mi | FDA grants fast track designation for HAYA Therapeutics' HTX-001 | ||
| Mi | Eisai and CORE Biomedicine agree on global licence for oncology pipeline | ||
| Di | Leadership changes afoot at two CGT biotechs | ||
| Di | Apnimed scouts $160m IPO to back late-stage sleep apnoea pill development | ||
| Di | BioMarin and n-Lorem partner on early research for ReNU syndrome therapy | ||
| Di | argenx signs agreement to buy Forte Biosciences for $2.2bn | ||
| Mo | Outlook Therapeutics wins FDA approval for Lytenava in wet AMD | ||
| Mo | Biointron introduces RushData platform for AI-driven antibody discovery | ||
| Mo | Kenvue's Tylenol with Naproxen gains FDA approval | ||
| 24.07. | Sanofi abandons eczema drug approval efforts in another blow to OX40 class | ||
| 24.07. | BeOne to invest $300m in US manufacturing facility expansion | ||
| 24.07. | FDA grants fast track designation for Lundbeck's Lu AH69593 | ||
| 23.07. | GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.